Imunon posts Q3 net loss of $3.4M, cash $5.3M; Phase 3 ovarian cancer study enrollment ahead

Imunon, Inc.

2025-Q3 EPS reported -$5.53 vs consensus -$1.84 ▼ miss (-200.3%)

Net loss of $3.4M ($1.16/sh) in Q3 2025 vs $4.8M ($3.76/sh) in Q3 2024; operating expenses down 30% to $3.5M.
Cash and equivalents $5.3M as of Sept 30, 2025; $4.5M raised from warrant exercises and ATM; runway into Q1 2026.
Phase 3 OVATION 3 study for IMNN-001 in advanced ovarian cancer enrollment exceeding expectations; Phase 2 data showed 13-month OS benefit.
R&D Day on Nov 10 highlighted investigator optimism and translational data; new data presented at SITC and AACR.
PlaCCine DNA vaccine platform proof-of-concept data presented; actively seeking partnerships.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.